Back to Market返回行情

DTIL Precision BioSciences, Inc.

USHealthcare
$8.76-4.37%ClosedMarket Cap: $112.4M

As of 2026-07-10 16:00

Why DTIL matters now

Precision BioSciences, Inc. (DTIL) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.76 with -4.37% on the session and $112.4M in market capitalization; recent performance reads 1-month -1.30% and YTD +63.70%.

The latest financial table shown here is Q1 2026, with revenue of $10.8M, net income of $-18.4M, and EPS of $-1.44. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -67.3%.

The latest indexable market news headline is "Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)" from Business Wire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $19.50; recent insider activity includes Buehler Kevin filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.15

P/S

1.94

EV/EBITDA

-0.41

DCF Value

$-12.53

FCF Yield

-67.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.0%

Operating Margin

-86.8%

Net Margin

-98.7%

ROE

-81.2%

ROA

-30.9%

ROIC

-28.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$10.8M$-18.4M$-1.44
Q4 2025$34.2M$19.2M$1.00
FY 2025$34.3M$-46.6M$-3.63
Q3 2025$13.0K$-21.8M$-1.84

Analyst Ratings

Consensus

Buy

Target (Consensus)

$19.50

Target (Median)

$19.50

Target Range

$19.00 - $20.00

Strong Buy: 0Buy: 5Hold: 0Sell: 0Strong Sell: 0
HC Wainwright & Co.Buy
2026-05-27

Trading Activity

Insider Trades

Buehler Kevindirector
Sell2026-06-05
Pire Shari Lisadirector
Sell2026-06-05
Germano Geno Jdirector
Sell2026-06-05
Frankel Stanleydirector
Sell2026-06-05
Brown Melindadirector
Sell2026-06-05

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.28

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.